Clinical Trial Update: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase [Phase 2, Phase 3]

View source ↗

Summary

Extension study update for long-term safety and outcomes in MPS II patients treated with idursulfase (Hunter syndrome).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome
• Mucopolysaccharidosis Ii

Drugs mentioned

• Idursulfase (idursulfase)

Snippet

Sponsor: Shire | Conditions: Hunter Syndrome, Mucopolysaccharidosis II (MPS II) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-03-17